Israel - English - Ministry of Health

taro international ltd, israel - bortezomib - powder for solution for injection - bortezomib 3.5 mg/vial - bortezomib - bortezomib is indicated for the treatment of patients with multiple myeloma.bortezomib is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - bortezomib - multiple myeloma - other antineoplastic agents - bortezomib hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Canada - English - Health Canada

teva canada limited - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

Malta - English - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

Malta - English - Medicines Authority

koanaa healthcare limited 4th floor, cavendish house, 369 burnt oak, broadway, edgware, ha85aw, middlesex, united kingdom - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - bortezomib - powder for solution for injection - 2.5 milligram(s) - bortezomib

Ireland - English - HPRA (Health Products Regulatory Authority)

aspire pharma limited - bortezomib - powder for solution for injection - 2.5 milligram(s) - bortezomib

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 2.5mg (as a mannitol boronic ester) - powder for injection - 2.5 mg - active: bortezomib 2.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.